摘要
目的研究原发性肝癌（PHC）患者血清白细胞介素-8（IL-8）、血管内皮生长因子（VEGF）与可溶性血管细胞粘附分子-1（sVCAM-）水平及临床意义。方法采用双抗体夹心酶联免疫吸附法（ELISA）检测15例原发性肝癌患者治疗前后血清IL-8、VEGF、sVCAM-水平，并与正常对照组比较。结果PHC患者治疗前血清IL-8、VEGF、sVCAM-较正常对照组明显升高（P均〈0．05）；PHC患者治疗两周后血清IL-8、VEGF、sVCAM-较治疗前降低（P均〈0．05），且较正常对照组仍有升高趋势（P均〈0．05）。结论原发性肝癌患者血清IL-8、VEGF、sVCAM-1水平增高，可能与原发性肝癌的发生、发展及侵袭有关。
Objective To investigate serum levels of interleukin-18 （ IL-18 ）, vascular endothelial growth factor （ VEGF ）, and soluble vascular cell adhesion molecule-1 （ sVCAM-1 ） in patients with primary hepatic carcinoma （ PHC ） and their clinical significance. Methods Serum levels of IL-18, VEGF, and sVCAM-1 were detected in 15 patients with PHC by enzyme-linked immunosorbent assay （ ELISA ） before and after treatment. The findings were compared with those from the healthy controls. Results The baseline levels of IL-18, VEGF, and sVCAM-1 were significantly higher in the patients with PHC than in the healthy controls （ P〈 0.05 ）. Levels of IL-18, VEGF, and sVCAM-1 were decreased two weeks after treatment as compared with the baselines （ P〈 0.05 ）, but were still higher than those from the healthy controls （ P 〈 0.05 ）. Conclusions An elevation in serum levels of IL-18, VEGF, and sVCAM-1 in patients with primary hepatic carcinoma may be associated with the genesis, development, and invasion of the malignancy.
出处
《国际医药卫生导报》
2012年第7期900-902,共3页
International Medicine and Health Guidance News
基金
惠州市科学技术局科研资助项目（y200505）
